{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:41:08Z","timestamp":1790516468105,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":5576,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1111\/j.1538-7836.2007.02663.x","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T20:25:32Z","timestamp":1187382332000},"page":"1904-1913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":281,"title":["Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors"],"prefix":"10.1016","volume":"5","author":[{"given":"B.A.","family":"KONKLE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.S.","family":"EBBESEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"ERHARDTSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.P.","family":"BIANCO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"LISSITCHKOV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"RUSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"SERBAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0010","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2516.2002.00626.x","article-title":"Inhibitors: resolving diagnostic and therapeutic dilemmas","volume":"8","author":"DiMichele","year":"2002","journal-title":"Haemophilia"},{"issue":"Suppl. 3","key":"10.1111\/j.1538-7836.2007.02663.x_bb0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2516.2006.01268.x","article-title":"Pathogenesis of haemophilic arthropathy","volume":"12","author":"Roosendaal","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.20162","article-title":"Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction","volume":"77","author":"Leissinger","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2516.2006.01204.x","article-title":"Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors","volume":"12","author":"Scalone","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0030","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2003-03-0941","article-title":"Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group","volume":"102","author":"Gringeri","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","article-title":"A longitudinal study of orthopaedic outcomes for severe factor\u2010VIII\u2010deficient haemophiliacs. The Orthopaedic Outcome Study Group","volume":"236","author":"Aledort","year":"1994","journal-title":"J Intern Med"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0022-3476(96)70076-8","article-title":"Episodic versus prophylactic infusions for hemophilia A: a cost\u2010effectiveness analysis","volume":"129","author":"Smith","year":"1996","journal-title":"J Pediatr"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0045","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1046\/j.1365-2516.1998.440498.x","article-title":"Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group","volume":"4","author":"Szucs","year":"1998","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2516.2005.01096.x","article-title":"Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors","volume":"11","author":"Young","year":"2005","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0055","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1046\/j.1365-2516.2000.00397.x","article-title":"The orthopaedic status of severe haemophiliacs in Spain","volume":"6","author":"Aznar","year":"2000","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0060","article-title":"Factor VIII inhibitor bypass activity (Feiba) for prophylaxis during immune tolerance induction (ITI) in patients with high\u2010responding inhibitors","volume":"96","author":"Kreuz","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0065","article-title":"Prophylactic use of FEIBA in children with hemophilia complicated by high\u2010titered inhibitors","volume":"100","author":"Valentino","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0070","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2516.2005.01143.x","article-title":"Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?","volume":"11","author":"Siegmund","year":"2005","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0075","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2516.2001.00553.x","article-title":"Rationale for the use of high dose rFVIIa in a high\u2010titre inhibitor patient with haemophilia B during major orthopaedic procedures","volume":"7","author":"Cooper","year":"2001","journal-title":"Haemophilia"},{"issue":"Suppl. 2","key":"10.1111\/j.1538-7836.2007.02663.x_bb0080","first-page":"57","article-title":"Prophylaxis of bleeding episodes in hemophilia A patients with inhibitors using rFVIIa: a multicenter experience","volume":"12","author":"Morfini","year":"2006","journal-title":"Haemophilia"},{"issue":"Suppl. 2","key":"10.1111\/j.1538-7836.2007.02663.x_bb0085","first-page":"107","article-title":"Prophylaxis with rFVIIa during immune\u2010tolerance treatment in a haemophilic child with a target joint","volume":"12","author":"Tagliaferri","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0090","series-title":"Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects","year":"2002"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0095","series-title":"ICH Harmonised Tripartite Guideline. Good Clinical Practice","year":"1996"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N","article-title":"The time trade\u2010off method: results from a general population study","volume":"5","author":"Dolan","year":"1996","journal-title":"Health Econ"},{"issue":"Suppl. 2","key":"10.1111\/j.1538-7836.2007.02663.x_bb0105","first-page":"3","article-title":"Prophylaxis: musculoskeletal evaluation","volume":"30","author":"Gilbert","year":"1993","journal-title":"Semin Hematol"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0110","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.V81.3.734.734","article-title":"Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation","volume":"81","author":"Morrissey","year":"1993","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1111\/j.1538-7836.2007.02663.x_bb0115","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/00001721-200004001-00009","article-title":"NovoSeven in immune tolerance therapy","volume":"11","author":"Brackmann","year":"2000","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1651-2227.1976.tb16525.x","article-title":"Haemophilia prophylaxis in Sweden","volume":"65","author":"Nilsson","year":"1976","journal-title":"Acta Paediatr Scand"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty\u2010five years\u2019 experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0130","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1046\/j.1365-2141.1996.420960.x","article-title":"The impact of prophyactic treatment on children with severe haemophilia","volume":"92","author":"Liesner","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0135","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2516.2004.00925.x","article-title":"Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A","volume":"1","author":"Villar","year":"2004","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0140","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1111\/j.1538-7836.2006.02166.x","article-title":"Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors","volume":"4","author":"Hedner","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0145","doi-asserted-by":"crossref","first-page":"E507","DOI":"10.1152\/ajpendo.2001.281.3.E507","article-title":"Metabolism of rabbit plasma\u2010derived factor vii in relation to prothrombin in rabbits","volume":"281","author":"Hatton","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-0037-1613832","article-title":"Haemostatic factors in human peripheral afferent lymph","volume":"83","author":"Miller","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-2003-37938","article-title":"Blood\u2010induced joint damage in hemophilia","volume":"29","author":"Rosendaal","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0160","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1365-2516.2003.00817.x","article-title":"On\u2010demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome","volume":"9","author":"Carlsson","year":"2003","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0165","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1046\/j.1365-2516.2002.00695.x","article-title":"Prophylactic versus on\u2010demand treatment strategies for severe haemophilia: a comparison of costs and long\u2010term outcome","volume":"8","author":"Fischer","year":"2002","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0170","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2796.1997.130135000.x","article-title":"Haemophilia prophylaxis in young patients \u2013 a long\u2010term follow\u2010up","volume":"241","author":"L\u00f6fqvist","year":"1997","journal-title":"J Intern Med"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0175","first-page":"515","article-title":"Assessing the effectiveness and cost\u2010effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand\u2019s disease","volume":"244","author":"Miners","year":"1998","journal-title":"J Intern Med"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0180","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00043426-199123000-00006","article-title":"Prophylaxis with factor concentrates in preventing hemophilic arthropathy","volume":"13","author":"Petrini","year":"1991","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0185","article-title":"Treatment with rFVIIa for prophylaxis of bleeding and reduction in inhibitor titer in hemophiliacs with inhibitors","volume":"98","author":"Young","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0190","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1055\/s-0037-1616550","article-title":"Effective prophylaxis with daily recombinant factor VIIa (rFVIIa\u2010Novoseven) in a child with high titre inhibitors and a target joint","volume":"86","author":"Saxon","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0195","first-page":"265a","article-title":"Efficacy and safety of factor VIII inhibitor bypass activity (Feiba) for long\u2010term prophylaxis in patients with high\u2010responding inhibitors","volume":"96","author":"Kreuz","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0200","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2516.2003.00771.x","article-title":"Long\u2010term FEIBA prophylaxis does not prevent progression of existing joint disease","volume":"9","author":"Hilgartner","year":"2003","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1111\/j.1538-7836.2007.02663.x_bb0205","article-title":"Long\u2010term prophylaxis with FEIBA in patients with high\u2010responding inhibitors","volume":"1","author":"Escuriola\u2010Ettinghausen","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2007.02663.x_bb0210","first-page":"104b","article-title":"High dose recombinant activated factor VII in a pediatric patient with factor VIII deficiency and high titer inhibitor","volume":"102","author":"Bryant","year":"2003","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2007.02663.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622102928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622102928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2007.02663.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:42:27Z","timestamp":1761532947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622102928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1538783622102928"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02663.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02663.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}